Brigham and Women's Hospital
The is a pilot, 12-week, double-blind, placebo-controlled, randomized trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching placebo (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD. The secondary aim is to assess the preliminary efficacy, safety, and tolerability of semaglutide for OUD.
Participants include N=46 men and women with DSM5 diagnosis of OUD who are newly initiating sublingual buprenorphine (SL-BUP), defined as within 60 days of enrollment. Only those participants who have attained stable SL-BUP dosing (i.e. no change in dose) for at least 30 days prior to enrollment and plan to remain on the SL-BUP for the duration of the trial will be eligible. Potential participants will be screened and enrolled only if they meet full inclusion criteria. After baseline procedures are complete, participants will be randomized to semaglutide or placebo. Following randomization, pa…
Inclusion Criteria * English-speaking adults aged 18 or older * DSM-5 diagnosis of severe opioid use disorder (OUD) * Receiving buprenorphine ≥16 mg/day or methadone ≥70 mg/day for at least 30 days prior to enrollment * Planning to continue buprenorphine or methadone treatment throughout the study * Willing to bring buprenorphine prescriptions to visits for dose counts (if applicable) * Willing to authorize communication between the study team and their MOUD prescriber via a 42 CFR release Exclusion Criteria * Active psychosis, suicidality, homicidality, or psychiatric conditions impairing…
This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
Placebo syringes of saline and matching volume will be produced by IDS.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.